Park National Has Lowered By $573,135 Its J P Morgan Chase & Company (JPM) Stake; Calithera Biosciences (CALA) Sentiment Is 1.22

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $250.11 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Park National Corp decreased J P Morgan Chase & Company (JPM) stake by 0.89% reported in 2017Q3 SEC filing. Park National Corp sold 6,033 shares as J P Morgan Chase & Company (JPM)’s stock declined 6.04%. The Park National Corp holds 669,044 shares with $63.90M value, down from 675,077 last quarter. J P Morgan Chase & Company now has $369.47 billion valuation. The stock decreased 4.42% or $4.99 during the last trading session, reaching $107.88. About 27.43 million shares traded or 85.21% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since February 9, 2017 and is uptrending. It has outperformed by 17.04% the S&P500.

Atika Capital Management Llc holds 1.06% of its portfolio in Calithera Biosciences, Inc. for 234,603 shares. Ascend Capital Llc owns 658,195 shares or 0.39% of their US portfolio. Moreover, Viking Global Investors Lp has 0.27% invested in the company for 2.62 million shares. The Massachusetts-based Adage Capital Partners Gp L.L.C. has invested 0.13% in the stock. Franklin Street Advisors Inc Nc, a North Carolina-based fund reported 35,580 shares.

The stock decreased 5.37% or $0.4 during the last trading session, reaching $7.05. About 481,492 shares traded. Calithera Biosciences, Inc. (CALA) has risen 278.82% since February 9, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Ratings analysis reveals 50% of Calithera Biosciences’s analysts are positive. Out of 2 Wall Street analysts rating Calithera Biosciences, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. CALA was included in 2 notes of analysts from October 25, 2016. Citigroup initiated the stock with “Sell” rating in Tuesday, October 25 report. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, January 5.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 15. They expect $-0.24 earnings per share, up 46.67% or $0.21 from last year’s $-0.45 per share. After $-0.17 actual earnings per share reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts 41.18% negative EPS growth.

Since August 21, 2017, it had 1 buying transaction, and 10 selling transactions for $23.24 million activity. 26,532 shares valued at $3.01M were sold by Scher Peter on Friday, January 19. 9,194 shares were sold by Lake Marianne, worth $1.03M. $902,608 worth of JPMorgan Chase & Co. (NYSE:JPM) was sold by Friedman Stacey. 16,434 JPMorgan Chase & Co. (NYSE:JPM) shares with value of $1.84 million were sold by BACON ASHLEY. The insider CROWN JAMES S bought 7,280 shares worth $825,327. The insider Petno Douglas B sold $5.43 million. Erdoes Mary E. also sold $7.31M worth of JPMorgan Chase & Co. (NYSE:JPM) on Saturday, January 13.

Park National Corp increased First Trust Enhanced Short Mat (FTSM) stake by 12,045 shares to 39,899 valued at $2.39M in 2017Q3. It also upped Merck & Company Inc (New) (NYSE:MRK) stake by 15,898 shares and now owns 422,012 shares. Cintas Corporation (NASDAQ:CTAS) was raised too.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.28, from 1.19 in 2017Q2. It is negative, as 65 investors sold JPM shares while 767 reduced holdings. 125 funds opened positions while 635 raised stakes. 2.50 billion shares or 7.05% less from 2.69 billion shares in 2017Q2 were reported. 36,960 were reported by Glaxis Mngmt Ltd Llc. Jacobus Wealth Mgmt accumulated 194,771 shares or 4.87% of the stock. Meridian Counsel has 6,114 shares for 0.33% of their portfolio. Millennium Management Ltd Liability Com reported 790,429 shares stake. Marshall Wace Ltd Liability Partnership holds 0.09% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM) for 20,965 shares. Rafferty Asset Lc, a New York-based fund reported 591,968 shares. Dillon And Inc holds 15,929 shares. Hollow Brook Wealth Ltd Liability holds 9,631 shares or 0.67% of its portfolio. 325,550 were accumulated by New Mexico Educational Retirement Board. Commonwealth Fincl Bank Of Australia accumulated 570,235 shares or 0.53% of the stock. Kentucky-based Barr E S & has invested 1.94% in JPMorgan Chase & Co. (NYSE:JPM). Paloma Prtn owns 107,325 shares. Markston Intl Limited Com has 143,230 shares. Checchi Cap Advisers Limited Liability Co owns 32,044 shares for 0.31% of their portfolio. Thrivent Financial For Lutherans, a Minnesota-based fund reported 158,322 shares.